FFM
JBIO

Fairmount Funds Management’s Jade Biosciences JBIO Stock Holding History

Fairmount Funds Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Hold
4,553,494
– – 6.69% 5
2026
Q1 		$64M Hold
4,553,494
– – 4.62% 8
2025
Q4 		$70.3M Buy
4,553,494
+1,333,126
+41% +$15.6M 5.35% 9
2025
Q3 		$27.8M Hold
3,220,368
– – 2.5% 14
2025
Q2 		$32.2M Buy
+3,220,368
New +$110M 4.17% 12

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fairmount Funds Management's JBIO Position: Q2 2026 in Review

Fairmount Funds Management held its Jade Biosciences (JBIO) position steady in Q2 2026 at 4,553,494 shares worth $101M. The position accounts for 6.69% of the portfolio, ranked #5.

Fairmount Funds Management first reported a position in JBIO in Q2 2025 and has held it in 5 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Fairmount Funds Management held 4,553,494 shares of Jade Biosciences worth $101M as of Q2 2026.
  • Fairmount Funds Management left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up 6.69% of Fairmount Funds Management's portfolio in Q2 2026, its #5 holding.
  • Fairmount Funds Management first reported a position in Jade Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.